Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
It is very uncertain whether the intervention changes adverse events ‐ shallow anterior chamber (very low certainty).
It is very uncertain whether duodenum‐preserving pancreatic resection changes adverse events (number of adverse events) compared with pancreaticoduodenectomy (very low certainty).
Hydrogel dressings showed no clear difference in adverse events (pain on dressing removal) compared with hydrogel dressings (low certainty).
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
It is very uncertain whether testosterone changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.
Testosterone as an add‐on to PDE5I showed no clear difference in treatment withdrawal due to adverse events compared with PDE5I alone (low certainty).
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
The intervention showed no clear difference in major adverse cardiovascular events (MACE) (low certainty).
It is very uncertain whether low‐intensity pulsed ultrasound changes adverse events Reported as skin irritation compared with control (very low certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
Casirivimab/imdevimab showed no clear difference in serious adverse events until data cut‐offb compared with placebo (low certainty).